Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending February 15, 2019. The report details the vesting of conditional share awards granted in 2016 under the GlaxoSmithKline 2009 Performance Share Plan (PSP) to Persons Discharging Managerial Responsibilities (PDMRs). The three-year performance period for these awards ran from January 1, 2016, to December 31, 2018.
Key Financial Metrics and Performance Outcomes
The filing provides specific performance metrics used to determine vesting levels for the 2016 PSP awards. The Remuneration Committee adjusted the Adjusted Free Cash Flow (AFCF) target to account for the timing of the Loss of Advair Exclusivity.
- Adjusted Free Cash Flow (AFCF): The Company achieved £13.18 billion against a threshold of £11.57 billion (increased by £0.22 billion). This resulted in a 77% vesting level for this portion of the award.
- Total Shareholder Return (TSR): GSK ranked 6th out of 10 comparator companies. This fell below the threshold vesting level, resulting in 0% vesting for this portion.
- R&D New Products: The Company achieved New Product sales of £10.435 billion, exceeding the maximum vesting level of £8.532 billion. This resulted in 100% vesting for this portion.
- Overall Vesting: The total vesting for the 2016 award was 41%, with 59% of the award lapsing.
Share prices at the point of vesting on February 14, 2019, were £15.66 for Ordinary Shares and $40.86 for American Depositary Shares (ADS).
Material Changes and Transaction Details
The filing reports the vesting of shares and ADSs for 12 PDMRs on February 14, 2019. All transactions were recorded at a price of £0.00 or $0.00, reflecting the vesting of awards rather than a market purchase. Notable transactions include:
- Ms. E. Walmsley (CEO): 140,762 Ordinary Shares vested.
- Mr. S. Dingemans (CFO): 151,161 Ordinary Shares vested, subject to a two-year holding period ending in 2021.
- Mr. B. McNamara (CEO, GSK Consumer Healthcare): 33,857 ADSs vested.
- Mr. J. Ford (SVP & General Counsel): 4,691 ADSs vested.
The filing notes that the Remuneration Committee also reviewed and agreed to adjust the AFCF targets for the 2017 and 2018 PSP awards, though specific performance details for those years are not included in this report.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, revenue outlook, or general risk factors. The primary contingency noted is the adjustment of the AFCF target for the 2016 awards to reduce outperformance attributable to the original timing assumption for the Loss of Advair Exclusivity. Additionally, specific holding periods apply to certain vested shares, such as the two-year restriction on shares vested to the CFO.
Key Facts for Investor Verification
- Verify the impact of the Adjusted Free Cash Flow target adjustment on executive compensation costs.
- Confirm the 41% total vesting rate for the 2016 PSP awards, driven by strong R&D performance but offset by sub-threshold Total Shareholder Return.
- Note the specific holding period restrictions on shares vested to the CFO (Mr. S. Dingemans) until 2021.
- Review the upcoming Remuneration Report for details on the adjusted AFCF targets for the 2017 and 2018 awards.